Your browser doesn't support javascript.
loading
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Jaeger, Hans; Orrell, Catherine; Nagimova, Firaya; Bredeek, Fritz; García Deltoro, Miguel; Swindells, Susan; Andrade-Villanueva, Jaime Federico; Wong, Alexander; Khuong-Josses, Marie-Aude; Van Solingen-Ristea, Rodica; van Eygen, Veerle; Crauwels, Herta; Ford, Susan; Talarico, Christine; Benn, Paul; Wang, Yuanyuan; Hudson, Krischan J; Chounta, Vasiliki; Cutrell, Amy; Patel, Parul; Shaefer, Mark; Margolis, David A; Smith, Kimberly Y; Vanveggel, Simon; Spreen, William.
Afiliación
  • Overton ET; University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: eoverton@uabmc.edu.
  • Richmond G; Nova Southeastern University, FL, USA.
  • Rizzardini G; Fatebenefratelli Sacco Hospital, Milan, Italy; School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Jaeger H; MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany.
  • Orrell C; Desmond Tutu HIV Foundation, University of Cape Town Medical School, Cape Town, South Africa.
  • Nagimova F; Republic Center for the Prevention and Control of AIDS and Infectious Diseases, Russia.
  • Bredeek F; Metropolis Medical, San Francisco, CA, USA.
  • García Deltoro M; General Hospital of Valencia, Valencia, Spain.
  • Swindells S; University of Nebraska Medical Center, Omaha, USA.
  • Andrade-Villanueva JF; Hospital Civil "Fray Antonio Alcalde", Guadalajara, Mexico.
  • Wong A; Department of Medicine, University of Saskatchewan, Regina, Saskatchewan, Canada.
  • Khuong-Josses MA; CH - Hôpital Delafontaine, Saint-Denis, France.
  • Van Solingen-Ristea R; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
  • van Eygen V; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Crauwels H; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Ford S; GlaxoSmithKline, Research Triangle Park, NC, USA.
  • Talarico C; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Benn P; ViiV Healthcare, Brentford, UK.
  • Wang Y; GlaxoSmithKline, Collegeville, PA, USA.
  • Hudson KJ; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Chounta V; ViiV Healthcare, Brentford, UK.
  • Cutrell A; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Patel P; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Shaefer M; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Margolis DA; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Smith KY; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Vanveggel S; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Spreen W; ViiV Healthcare, Research Triangle Park, NC, USA.
Lancet ; 396(10267): 1994-2005, 2021 12 19.
Article en En | MEDLINE | ID: mdl-33308425
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridonas / Infecciones por VIH / VIH-1 / Fármacos Anti-VIH / Rilpivirina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridonas / Infecciones por VIH / VIH-1 / Fármacos Anti-VIH / Rilpivirina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article